Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.

Peptide analogs of growth hormone-releasing hormone (GHRH) can potentially interact with vasoactive intestinal peptide (VIP) receptors (VPAC(1)-R and VPAC(2)-R) because of the structural similarities of these two hormones and their receptors. We synthesized four new analogs related to GHRH (JV-1-50, JV-1-51, JV-1-52, and JV-1-53) with decreased GHRH antagonistic activity and increased VIP antagonistic potency. To characterize various peptide analogs for their antagonistic activity on receptors for GHRH and VIP, we developed assay systems based on superfusion of rat pituitary and pineal cells. Receptor-binding affinities of peptides to the membranes of these cells were also evaluated by radioligand competition assays. Previously reported GHRH antagonists JV-1-36, JV-1-38, and JV-1-42 proved to be selective for GHRH receptors, because they did not influence VIP-stimulated VPAC(2) receptor-dependent prolactin release from pituitary cells or VPAC(1) receptor-dependent cAMP efflux from pinealocytes but strongly inhibited GHRH-stimulated growth hormone (GH) release. Analogs JV-1-50, JV-1-51, and JV-1-52 showed various degrees of VPAC(1)-R and VPAC(2)-R antagonistic potency, although also preserving a substantial GHRH antagonistic effect. Analog JV-1-53 proved to be a highly potent VPAC(1) and VPAC(2) receptor antagonist, devoid of inhibitory effects on GHRH-evoked GH release. The antagonistic activity of these peptide analogs on processes mediated by receptors for GHRH and VIP was consistent with the binding affinity. The analogs with antagonistic effects on different types of receptors expressed on tumor cells could be utilized for the development of new approaches to treatment of various human cancers.

[1]  A. Schally,et al.  Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers. , 2000, Endocrinology.

[2]  A. Schally,et al.  Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents , 1999, Trends in Endocrinology & Metabolism.

[3]  A. Schally,et al.  Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Schally,et al.  Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Robberecht,et al.  Analogues of VIP, Helodermin, and PACAP Discriminate between Rat and Human VIP1 and VIP2 Receptors a , 1998, Annals of the New York Academy of Sciences.

[6]  R. Ross.  Growth Hormone Secretagogues in Clinical Practice , 1998 .

[7]  V. Csernus,et al.  Adrenergic and peptidergic control of the regulation of cAMP efflux and melatonin secretion from perifused rat pineal gland , 1998, Endocrine.

[8]  S. Rawlings,et al.  International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. , 1998, Pharmacological reviews.

[9]  P. de Neef,et al.  Vasoactive intestinal peptide modification at position 22 allows discrimination between receptor subtypes. , 1998, European journal of pharmacology.

[10]  H. Vaudry,et al.  Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland , 1998, Neuroscience.

[11]  S. Schiffmann,et al.  Autoradiographic Visualization of the Receptor Subclasses for Vasoactive Intestinal Polypeptide (VIP) in Rat Brain , 1997, Peptides.

[12]  P. Robberecht,et al.  In Vitro Properties of a High Affinity Selective Antagonist of the VIP1 Receptor , 1997, Peptides.

[13]  A. Schally,et al.  Synthesis and In Vitro Evaluation of New Potent Antagonists of Growth Hormone-Releasing Hormone (GH-RH) , 1997, Peptides.

[14]  T. Moody,et al.  Peptides and growth factors in non-small cell lung cancer , 1996, Peptides.

[15]  J C Reubi,et al.  In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  E. Hooghe-Peters,et al.  Differential alternative splicing of PACAP receptor in pituitary cell subpopulations , 1995, Molecular and Cellular Endocrinology.

[17]  A. Schally,et al.  Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Gelato.  Growth Hormone-Releasing Hormone: Clinical Perspectives , 1994 .

[19]  S. Goldring,et al.  Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family , 1993, Trends in Endocrinology & Metabolism.

[20]  A. Schally,et al.  A method for evaluation of activity of antagonistic analogs of growth hormone-releasing hormone in a superfusion system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Schally,et al.  Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone. , 1993, Receptor.

[22]  M. Thorner,et al.  Molecular cloning and expression of a human anterior pituitary receptor for growth hormone-releasing hormone. , 1993, Molecular endocrinology.

[23]  R. Campbell,et al.  Evolution of the growth hormone-releasing factor (GRF) family of peptides. , 1992, Growth regulation.

[24]  K. Mayo.  Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. , 1992, Molecular endocrinology.

[25]  D. Coy,et al.  Human growth hormone-releasing hormone analogues with much improved in vitro growth hormone-releasing potencies in rat pituitary cells. , 1991, European journal of pharmacology.

[26]  V. Csernus,et al.  Long‐Term Dynamic in vitro System for Investigating Rat Pineal Melatonin Secretion , 1991, Journal of neuroendocrinology.

[27]  O. Rorstad,et al.  Receptors for vasoactive intestinal peptide in rat anterior pituitary glands: localization of binding to lactotropes. , 1990, Endocrinology.

[28]  N. Ling,et al.  Synthetic analogs of growth hormone-releasing factor with antagonistic activity in vitro. , 1990, Biochemical and biophysical research communications.

[29]  C. Polychronakos,et al.  Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. , 1989, Anticancer research.

[30]  D. Coy,et al.  Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas , 1986, Peptides.

[31]  G A McPherson,et al.  Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. , 1985, Journal of pharmacological methods.

[32]  D. Coy,et al.  Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. , 1985, Endocrinology.

[33]  D. Coy,et al.  Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. , 1985, Endocrinology.